体重变化对MASLD不同组织学终点的影响:系统综述与荟萃分析
纤维化≥1期改善且MASH未恶化的比例为0.17(95%CI 0.13-0.22)。
要点
- 体重下降>3%与MASH完全缓解率显著提高相关(0.25 vs 总体0.12)
- 纤维化≥1期改善且MASH未恶化比例为0.17(95%CI 0.13-0.22)
- BMI、2型糖尿病患病率及西班牙裔/拉丁裔 ethnicity 不影响组织学应答
核心结论
- 即使 modest 的体重下降也与MASH缓解相关,且BMI、2型糖尿病、西班牙裔/拉丁裔 ethnicity 不影响MASH缓解或纤维化改善。
主要发现
- 体重下降>3%者MASH完全缓解且纤维化未恶化比例为0.25(95%CI 0.20-0.30,P<0.001)。
- 纤维化≥1期改善且MASH未恶化的总比例为0.17(95%CI 0.13-0.22,I²=62%)。
- 基线BMI、2型糖尿病患病率、西班牙裔/拉丁裔 ethnicity 亚组间无显著差异。
- 平均年龄显著贡献异质性(P=0.021,R²=43%)。
临床怎么用
- 体重管理是MASLD/MASH治疗的核心,即使 modest 体重下降(>3%)也可实现MASH缓解。
- BMI、2型糖尿病、西班牙裔/拉丁裔 ethnicity 不影响组织学应答,生活方式干预应适用于所有人群。
- 本研究的比例估计可作为未来临床试验设计时组织学应答的基准参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Weight loss is the cornerstone of treatment for metabolic dysfunction-associated liver disease (MASLD); however, its impact on liver histology across patient subgroups remains incompletely characterized. This systematic review and meta-analysis aimed to quantify the effects of body weight change across multiple histological endpoints in patients with biopsy-proven MASLD. METHODS: PubMed, EMBASE, MEDLINE (Ovid), and Google Scholar were searched from inception for trials reporting percentage change in body weight in MASLD or metabolic dysfunction-associated steatohepatitis (MASH) patients with paired liver biopsies. Proportions of patients achieving the primary outcomes: Complete resolution of MASH without worsening of fibrosis and ≥1-stage fibrosis improvement without worsening of MASH were analyzed using random-effects proportional meta-analysis. Revised Cochrane risk of bias tool for randomized trials 2 and Risk of Bias in Nonrandomized Studies of Interventions I were used for assessing risk of bias. RESULTS: Twenty-six studies with 1,963 participants were included. Proportion attaining complete resolution of MASH without worsening of fibrosis was 0.12 (95% confidence interval [CI]: 0.08-016, I 2 = 76%) which significantly improved with observed weight loss >3% (0.25, 95% CI: 0.20-0.30, P < 0.001). Mean age significantly contributed to heterogeneity ( P = 0.021, R 2 = 43%). Proportion attaining ≥1-stage fibrosis improvement without worsening of MASH was 0.17 (95% CI: 0.13-0.22, I 2 = 62%). No significant differences were found based on baseline body mass index, type 2 diabetes mellitus prevalence, or Hispanic/Latino ethnicity. DISCUSSION: Even modest observed weight loss is associated with MASH resolution. MASH resolution and ≥1-stage fibrosis improvement are not affected by body mass index, type 2 diabetes mellitus, or Hispanic/Latino ethnicity, reinforcing the importance of lifestyle interventions across populations. The proportions observed serve as benchmark estimates of histological response for future clinical trial design.
引用
- Jayabalan D, Dhakal S, Chandra J, et al. The Impact of Body Weight Change on Liver Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Across Various Histological Endpoints: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2026. PMID: 41510965. doi:10.14309/ajg.0000000000003918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。